In this article, we will discuss Irinotecan (Dosage Overview). So, let’s get started.
Irinotecan is a topoisomerase inhibitor indicated for:
• First-line therapy in combination with 5-fluorouracil and leucovorin for
patients with metastatic carcinoma of the colon or rectum.
• Patients with metastatic carcinoma of the colon or rectum whose disease
has recurred or progressed following initial fluorouracil-based therapy.
Dosage
• Colorectal cancer combination regimen 1: Irinotecan 125 mg/m² intravenous infusion over 90 minutes on days 1, 8, 15, 22 with LV 20 mg/m² intravenous bolus infusion on days 1, 8, 15, 22 followed by 5-FU intravenous bolus infusion on days 1, 8, 15, 22 every 6 weeks.
• Colorectal cancer combination regimen 2: Irinotecan 180 mg/m²
intravenous infusion over 90 minutes on days 1, 15, 29 with LV 200 mg/m² intravenous infusion over 2 hours on days 1, 2, 15, 16, 29, 30 followed by 5-FU 400 mg/m2 intravenous bolus infusion on days 1, 2, 15, 16, 29, 30 and 5-FU 600 mg/m² intravenous infusion over 22 hours on days 1, 2, 15, 16, 29, 30.
• Colorectal cancer single agent regimen 1: Irinotecan 125 mg/m² intravenous infusion over 90 minutes on days 1, 8, 15, 22 then 2-week rest.
• Colorectal cancer single agent regimen 2: Irinotecan 350 mg/m² intravenous infusion over 90 minutes on day 1 every 3 weeks.